ArticleMedicine2026
Association between atherogenic index of plasma and depression in patients with type 2 diabetes mellitus: A cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a major global public health issue and is particularly prevalent but often underrecognized among patients with type 2 diabetes mellitus (T2DM). Metabolic dysregulation has been closely linked to depressive symptoms, and the atherogenic index of plasma (AIP), a marker of dyslipidemia, may be associated with depressive symptoms. However, evidence regarding this association in T2DM populations remains limited. This study aimed to investigate the association between AIP and the risk of depressive symptoms in patients with T2DM using data from the National Health and Nutrition Examination Survey 2011 to 2016. Data were obtained from National Health and Nutrition Examination Survey 2011 to 2016 and included participants with T2DM. AIP was the primary exposure, and clinically significant depressive symptoms were assessed using the Patient Health Questionnaire-9. Multivariable logistic regression was used to evaluate the association between AIP and depressive symptoms. Smooth curve fitting was applied to examine potential nonlinearity, and receiver operating characteristic curve analysis was performed to assess the discriminative ability of AIP. Subgroup and interaction analyses were conducted to test the robustness of the association. A total of 1439 patients with T2DM were included, of whom 180 (12.51%) had clinically significant depressive symptoms. Higher AIP was associated with approximately 2-fold higher odds of depressive symptoms after adjustment for covariates in the adjust II model (odds ratio = 2.0, 95% confidence interval: 1.1-3.6, P = .021). Receiver operating characteristic analysis showed statistically significant but limited discriminative ability of AIP for depressive symptoms, with an area under the curve of 0.5781 (95% confidence interval: 0.5341-0.6221). Subgroup analyses showed consistent associations across sex, age, education level, smoking status, and lipid levels, with no significant interactions (P for interaction >.05). Smooth curve fitting showed no evidence of nonlinearity, suggesting a linear positive association between AIP and depressive symptoms (P for nonlinearity = .213). In patients with T2DM, higher AIP levels were significantly associated with increased risk of depressive symptoms. AIP may serve as a supplementary indicator for assessing the risk of depressive symptoms in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.